Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
STRM.BIO logo — Fulfilling the promise of gene therapy.

STRM.BIO

Fulfilling the promise of gene therapy.

Founded 2019 United States Boston, United States 14 employees Grant Total: $2.10M Biotechnology

General Information

Company Name STRM.BIO
Founded Year 2019
Location United States Boston, United States +1
Employees 14
Industries Biotechnology
Funding Stage Grant
Social

Get notified when STRM.BIO moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About STRM.BIO

STRM.BIO is a Boston-based biotechnology startup founded in 2019, with a goal to revolutionize gene therapy using extracellular vesicles (EVs). Backed by venture capital, notably including a grant investment from the Bill & Melinda Gates Foundation in October 2023, this pre-clinical company is dedicated to making gene therapy more accessible and effective. Unlike traditional viral carriers, EVs offer natural nucleic acid and protein delivery with specific targeting and low immunogenicity, providing an ideal platform for gene therapy innovation. STRM.BIO's pioneering EV platform is poised to unlock a new class of therapeutics, potentially addressing rare diseases and enhancing existing treatment approaches. The company's commitment to democratizing gene therapy and bringing hope to patients worldwide is evident in their vision to recruit exceptional talents to turn this vision into reality.

Taxonomy: gene therapy, extracellular vesicles, EVs, pre-clinical, VC-backed, Boston, therapeutics, rare diseases, in vivo, nucleic acids, proteins, targeting capabilities, immunogenicity, commercial manufacture

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
03 Oct 2023
Seed Round •••••• 1
Investor
11 May 2023
Grant •••••• 1
Investor
26 Jul 2022

STRM.BIO Alternatives & Competitors

STRM.BIO vs
Coave Therapeutics
Coave Therapeutics France

Coave therapeutics new brand for Horama

Grant
36 employees
Biotechnology, Life Sciences
STRM.BIO vs
BioViva USA Inc.
BioViva USA Inc. United States

Data science and gene therapy company set to revolutionize heatlhcare

Equity Crowdfunding
5 employees
Biotechnology, Health Care
STRM.BIO vs
Forge Biologics
Forge Biologics United States

A member of Ajinomoto Bio-Pharma Services

Series C
441 employees
Biotechnology, Health Care
Compare STRM.BIO vs Forge Biologics

FAQ About STRM.BIO

Fulfilling the promise of gene therapy.
STRM.BIO was founded in 2019.
STRM.BIO is headquartered in Boston, United States.
STRM.BIO operates in the following industries: Biotechnology.
STRM.BIO has approximately 14 employees.
STRM.BIO has completed 3 funding rounds, raising a total of $2.10M. The latest funding stage is Grant.
Top alternatives and competitors to STRM.BIO include Coave Therapeutics, BioViva USA Inc., Forge Biologics, Ocugen, Alliance for Cancer Gene Therapy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
STRM.BIO and Coave Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors STRM.BIO and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes